← Back to patent-cliff list
Tasurgratinib
Tier C — Watch / tradeTasurgratinib
Eisai Co., Ltd.
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR1, FGFR3, FGFR2
Brand：TASFYGO
Indications (approved)：Biliary tract cancer, Bile duct cancer
Regional status
US
-
EU
No progress
2020-09-09
China
Approved
2026-09-02
Japan
Approved
2024-09-24
Synthetic routes & intermediates4 routes
Originator routes × 0Optimised (non-patent) × 4Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OptimisedRoute 1Steps 9 · Total yield /
(I)859946-1-a139-85-5(II)859946-1-a,(II)859946-1-c6482-24-2(III)859946-1-a943751-08-4(IV)859946-1-a1622205-57-5(V)859946-1-a75-52-5(VI)859946-1-a1622205-58-6(VII)859946-1-a,(VII)859946-1-c1622205-59-7(VIII)859946-1-a245056-66-0(IX)859946-1-a19798-80-2(X)859946-1-a1622205-61-1(XI)859946-1-a1622205-62-2(XII)859946-1-a,(XII)859946-1-c1943-79-9(XIII)859946-1-a593-51-1(XIV)859946-1-a1885-14-9(XIX)859946-1-a23147-58-2(XV)859946-1-a,(XV)859946-1-c1622205-63-3(XVI)859946-1-a,(XVI)859946-1-b149353-75-3(XVII)859946-1-a1622204-19-6(XVIII)859946-1-a141-46-8API · Tasurgratinib
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)859946-1-a | 139-85-5 | 3,4-Dihydroxybenzaldehyde |
| (II)859946-1-a,(II)859946-1-c | 6482-24-2 | 1-Bromo-2-methoxyethane |
| (III)859946-1-a | 943751-08-4 | 3-Hydroxy-4-(2-methoxyethoxy)benzaldehyde |
| (IV)859946-1-a | 1622205-57-5 | 3-(Benzyloxy)-4-(2-methoxyethoxy)benzaldehyde |
| (V)859946-1-a | 75-52-5Available | Nitrocarbol |
| (VI)859946-1-a | 1622205-58-6 | 2-(Benzyloxy)-1-(2-methoxyethoxy)-4-[(E)-2-nitroethenyl]benzene |
| (VII)859946-1-a,(VII)859946-1-c | 1622205-59-7 | 6-(2-Methoxyethoxy)-1H-indol-5-ol |
| (VIII)859946-1-a | 245056-66-0 | N-(4-Chloropyridin-2-yl)acetamide |
| (IX)859946-1-a | 19798-80-2Available | 2-Amino-4-chloropyridine |
| (X)859946-1-a | 1622205-61-1 | N-(4-[[6-(2-Methoxyethoxy)-1H-indol-5-yl]oxy]pyridin-2-yl)acetamide |
| (XI)859946-1-a | 1622205-62-2 | 4-[[6-(2-Methoxyethoxy)-1H-indol-5-yl]oxy]pyridin-2-amine |
| (XII)859946-1-a,(XII)859946-1-c | 1943-79-9 | Phenyl methylcarbamate |
| (XIII)859946-1-a | 593-51-1 | Aminomethane hydrochloride |
| (XIV)859946-1-a | 1885-14-9Available | Carbonochloridic acid phenyl ester |
| (XIX)859946-1-a | 23147-58-2 | 1,4-Dioxane-2,5-diol |
| (XV)859946-1-a,(XV)859946-1-c | 1622205-63-3 | 5-[(2-Aminopyridin-4-yl)oxy]-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide |
| (XVI)859946-1-a,(XVI)859946-1-b | 149353-75-3 | 4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]benzoic acid |
| (XVII)859946-1-a | 1622204-19-6 | 6-(2-Methoxyethoxy)-N-methyl-5-([2-[4-(piperidin-4-yl)benzamido]pyridin-4-yl]oxy)-1H-indole-1-carboxamide |
| (XVIII)859946-1-a | 141-46-8 | 2-Oxidanylethanal |
OptimisedRoute 2Steps 4 · Total yield /
(XVI)859946-1-a,(XVI)859946-1-b149353-75-3(XX)859946-1-b771-99-3(XXI)859946-1-b32245-87-7(XXII)859946-1-b149353-96-8(XXIII)859946-1-b149353-84-4(XXIV)859946-1-b769944-78-7API · Tasurgratinib
| Code | CAS No. | Intermediate |
|---|---|---|
| (XVI)859946-1-a,(XVI)859946-1-b | 149353-75-3 | 4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]benzoic acid |
| (XX)859946-1-b | 771-99-3 | 4-Phenylpiperidine |
| (XXI)859946-1-b | 32245-87-7 | 1-(4-Phenylpiperidin-1-yl)ethan-1-one |
| (XXII)859946-1-b | 149353-96-8 | 4-(1-Acetylpiperidin-4-yl)benzoic acid |
| (XXIII)859946-1-b | 149353-84-4 | 4-(Piperidin-4-yl)benzoic acid hydrogen chloride |
| (XXIV)859946-1-b | 769944-78-7 | N-Boc-4-(4-bromophenyl)piperidine |
OptimisedRoute 3Steps 10 · Total yield /
(II)859946-1-a,(II)859946-1-c6482-24-2(VII)859946-1-a,(VII)859946-1-c1622205-59-7(XII)859946-1-a,(XII)859946-1-c1943-79-9(XV)859946-1-a,(XV)859946-1-c1622205-63-3(XXIX)859946-1-c3598-13-8(XXV)859946-1-c2620-44-2(XXVI)859946-1-c873-75-6(XXVII)859946-1-c—(XXVIII)859946-1-c—(XXX)859946-1-c—(XXXI)859946-1-c—(XXXII)859946-1-c1124-33-0(XXXIII)859946-1-c—(XXXIV)859946-1-c107-45-9(XXXV)859946-1-c—(XXXVI)859946-1-c—(XXXVII)859946-1-c—API · Tasurgratinib
| Code | CAS No. | Intermediate |
|---|---|---|
| (II)859946-1-a,(II)859946-1-c | 6482-24-2 | 1-Bromo-2-methoxyethane |
| (VII)859946-1-a,(VII)859946-1-c | 1622205-59-7 | 6-(2-Methoxyethoxy)-1H-indol-5-ol |
| (XII)859946-1-a,(XII)859946-1-c | 1943-79-9 | Phenyl methylcarbamate |
| (XV)859946-1-a,(XV)859946-1-c | 1622205-63-3 | 5-[(2-Aminopyridin-4-yl)oxy]-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide |
| (XXIX)859946-1-c | 3598-13-8 | 2-(4-Chlorophenoxy)acetonitrile |
| (XXV)859946-1-c | 2620-44-2 | 5-Nitro-2H-1,3-benzodioxole |
| (XXVI)859946-1-c | 873-75-6 | (4-Bromophenyl)methanol |
| (XXVII)859946-1-c | - | 2-[(4-Bromobenzyl)oxy]-5-nitrophenol |
| (XXVIII)859946-1-c | - | 1-[(4-Bromobenzyl)oxy]-2-(2-methoxyethoxy)-4-nitrobenzene |
| (XXX)859946-1-c | - | [5-[(4-Bromophenyl)methoxy]-4-(2-methoxyethoxy)-2-nitrophenyl]acetonitrile |
| (XXXI)859946-1-c | - | tert-Butyl 5-hydroxy-6-(2-methoxyethoxy)-1H-indole-1-carboxylate |
| (XXXII)859946-1-c | 1124-33-0 | 4-Nitropyridine 1-oxide |
| (XXXIII)859946-1-c | - | tert-Butyl 6-(2-methoxyethoxy)-5-[(1-oxo-1lambda5-pyridin-4-yl)oxy]-1H-indole-1-carboxylate |
| (XXXIV)859946-1-c | 107-45-9 | 1,1,3,3-Tetramethylbutylamine |
| (XXXV)859946-1-c | - | tert-Butyl 6-(2-methoxyethoxy)-5-([2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl]oxy)-1H-indole-1-carboxylate |
| (XXXVI)859946-1-c | - | 4-[[6-(2-Methoxyethoxy)-1H-indol-5-yl]oxy]-N-(2,4,4-trimethylpentan-2-yl)pyridin-2-amine |
| (XXXVII)859946-1-c | - | 6-(2-Methoxyethoxy)-N-methyl-5-([2-[(2,4,4-trimethylpentan-2-yl)amino]pyridin-4-yl]oxy)-1H-indole-1-carboxamide |
OptimisedRoute 4Steps 3 · Total yield /
(I)663167-2-a3612-20-2(II)663167-2-a100-58-3(III)663167-2-a63843-83-4(IV)663167-2-a38025-45-5(V)663167-2-a771-99-3API · Tasurgratinib
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)663167-2-a | 3612-20-2 | 1-(Phenylmethyl)-4-piperidinone |
| (II)663167-2-a | 100-58-3 | Bromo(phenyl)magnesium |
| (III)663167-2-a | 63843-83-4 | 1-Benzyl-4-phenylpiperidin-4-ol |
| (IV)663167-2-a | 38025-45-5 | 1-Benzyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| (V)663167-2-a | 771-99-3 | 4-Phenylpiperidine |
Frequently asked questions
What are the approved indications of Tasurgratinib?
Approved indications include: Biliary tract cancer, Bile duct cancer.
When does the Tasurgratinib patent expire?
No public expiry year is available for Tasurgratinib yet; this page updates once verified.
How many synthesis routes are recorded for Tasurgratinib?
4 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Tasurgratinib intermediates?
3 intermediate CAS of Tasurgratinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Tasurgratinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29